| Year |
Citation |
Score |
| 2023 |
Zhang L, Jiang Y, Zhang G, Wei S. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Frontiers in Immunology. 14: 1238233. PMID 37731483 DOI: 10.3389/fimmu.2023.1238233 |
0.335 |
|
| 2023 |
Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, ... ... Zhang G, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. PMID 36634707 DOI: 10.1038/s41586-023-05704-6 |
0.309 |
|
| 2022 |
Wei S, Yin D, Yu S, Lin X, Savani MR, Du K, Ku Y, Wu D, Li S, Liu H, Tian M, Chen Y, Bowie M, Hariharan S, Waitkus M, ... ... Zhang G, et al. Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35247901 DOI: 10.1158/1078-0432.CCR-21-0833 |
0.453 |
|
| 2021 |
Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, et al. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal For Immunotherapy of Cancer. 9. PMID 34937742 DOI: 10.1136/jitc-2021-003339 |
0.399 |
|
| 2021 |
Du K, Wei S, Wei Z, Frederick DT, Miao B, Moll T, Tian T, Sugarman E, Gabrilovich DI, Sullivan RJ, Liu L, Flaherty KT, Boland GM, Herlyn M, Zhang G. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications. 12: 6023. PMID 34654806 DOI: 10.1038/s41467-021-26299-4 |
0.458 |
|
| 2021 |
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, ... ... Zhang G, et al. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34593527 DOI: 10.1158/1078-0432.CCR-21-0374 |
0.477 |
|
| 2021 |
Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, et al. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Research. PMID 34462276 DOI: 10.1158/0008-5472.CAN-20-1496 |
0.547 |
|
| 2021 |
Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. PMID 34304249 DOI: 10.1038/s41388-021-01911-5 |
0.538 |
|
| 2021 |
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine. PMID 33941922 DOI: 10.1038/s41591-021-01331-8 |
0.522 |
|
| 2020 |
Wang L, Gao Y, Zhang G, Li D, Wang Z, Zhang J, Hermida LC, He L, Wang Z, Si J, Geng S, Ai R, Ning F, Cheng C, Deng H, et al. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine. 12. PMID 32908002 DOI: 10.1126/Scitranslmed.Aax2282 |
0.455 |
|
| 2020 |
Marusak C, Thakur V, Li Y, Freitas JT, Zmina P, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, ... ... Zhang G, et al. Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32820016 DOI: 10.1158/1078-0432.Ccr-19-2773 |
0.519 |
|
| 2020 |
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez-Gomez MJ, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan Hersh E, Livneh I, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Molecular Cancer Research : McR. PMID 32571981 DOI: 10.1158/1541-7786.Mcr-20-0291 |
0.526 |
|
| 2020 |
Lee J, Labrie M, Yong G, Camp T, Ma H, Grout M, Xu W, Beasley G, Schuchter LM, McGettigan S, O'Rourke DM, Herlyn M, Corless CL, Mills GB, Zhang G. Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies. Journal of Clinical Oncology. 38: e22015-e22015. DOI: 10.1200/Jco.2020.38.15_Suppl.E22015 |
0.607 |
|
| 2020 |
Atay C, Kwak T, Lavilla-Alonso S, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. Abstract B41: BRAF targeting sensitizes resistant melanoma to cytotoxic T cells Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B41 |
0.626 |
|
| 2019 |
Kwon SM, Budhu A, Woo HG, Chaisaingmongkol J, Dang H, Forgues M, Harris CC, Zhang G, Auslander N, Ruppin E, Mahidol C, Ruchirawat M, Wang XW. Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer. Scientific Reports. 9: 16930. PMID 31729408 DOI: 10.1038/S41598-019-52578-8 |
0.357 |
|
| 2019 |
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T, Bock C, Zhang G, Herlyn M, Glatz K, Läubli H, Mertz KD, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications. 10: 4186. PMID 31519915 DOI: 10.1038/S41467-019-12160-2 |
0.551 |
|
| 2019 |
Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, et al. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports. 28: 1971-1980.e8. PMID 31433975 DOI: 10.1016/J.Celrep.2019.07.084 |
0.486 |
|
| 2019 |
Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, ... ... Zhang G, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253 |
0.548 |
|
| 2019 |
Sugarman ET, Zhang G, Shay JW. In perspective: An update on telomere targeting in cancer. Molecular Carcinogenesis. PMID 31062416 DOI: 10.1002/Mc.23035 |
0.375 |
|
| 2019 |
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker BL, Yang R, Feltcher C, Peng K, Feng C, et al. Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 10: 1211. PMID 30858377 DOI: 10.1038/S41467-019-09195-W |
0.391 |
|
| 2019 |
Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology. 15: e8323. PMID 30858180 DOI: 10.15252/Msb.20188323 |
0.56 |
|
| 2019 |
Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, et al. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30765391 DOI: 10.1158/1078-0432.Ccr-18-2725 |
0.602 |
|
| 2019 |
Jerby L, Shah P, Cuoco MS, Rodman C, Su M, Melms JM, Leeson R, Kanodia A, Mei S, Lin J, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, et al. Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A082 |
0.593 |
|
| 2019 |
Izar B, Jerby-Arnon L, Tirosh I, Shah P, Cuoco MC, Rodman C, Su M, Melms JC, Leeson R, Kanodia A, Lin J, Boland GM, Zhang G, Hodi FS, Sorger PK, et al. Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Sy45-04 |
0.352 |
|
| 2019 |
Das A, Lee JS, Zhang G, Wang Z, Amzallag A, Boland G, Hannenhalli S, Herlyn M, Benes C, Gutkind JS, Flaherty K, Ruppin E. Abstract LB-149: Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-149 |
0.586 |
|
| 2018 |
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, et al. Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 9: 5426. PMID 30575721 DOI: 10.1038/S41467-018-07126-9 |
0.547 |
|
| 2018 |
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, ... ... Zhang G, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery. PMID 30563872 DOI: 10.1158/2159-8290.Cd-18-0348 |
0.578 |
|
| 2018 |
Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, et al. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 30532003 DOI: 10.1038/S41586-018-0814-7 |
0.526 |
|
| 2018 |
Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discovery. PMID 30442709 DOI: 10.1158/2159-8290.Cd-18-0706 |
0.561 |
|
| 2018 |
Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/J.Cell.2018.09.006 |
0.599 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30333558 DOI: 10.1038/S41591-018-0247-8 |
0.438 |
|
| 2018 |
Pathria G, Scott DA, Feng Y, Sang Lee J, Fujita Y, Zhang G, Sahu AD, Ruppin E, Herlyn M, Osterman AL, Ronai ZA. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. The Embo Journal. PMID 30209241 DOI: 10.15252/Embj.201899735 |
0.57 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30127394 DOI: 10.1038/S41591-018-0157-9 |
0.506 |
|
| 2018 |
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. PMID 30089911 DOI: 10.1038/S41586-018-0392-8 |
0.447 |
|
| 2018 |
Huang M, Qi TF, Li L, Zhang G, Wang Y. A targeted quantitative proteomic approach assesses the reprogramming of small GTPases during melanoma metastasis. Cancer Research. PMID 30072397 DOI: 10.1158/0008-5472.Can-17-3811 |
0.412 |
|
| 2018 |
Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine. PMID 30038220 DOI: 10.1038/S41591-018-0116-5 |
0.575 |
|
| 2018 |
Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29959144 DOI: 10.1158/1078-0432.Ccr-17-3697 |
0.397 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.61 |
|
| 2018 |
Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.Ccr-17-2773 |
0.538 |
|
| 2018 |
Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, et al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9: 8206-8222. PMID 29492189 DOI: 10.18632/Oncotarget.23654 |
0.494 |
|
| 2018 |
Liu D, Zhang G, Shi A, Izar B, Heyde A, Kasumova GG, Frederick DT, Moll T, Sahu A, Ruppin E, Nowak M, Kellis M, Herlyn M, Lawrence DP, Flaherty K, et al. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. Journal of Clinical Oncology. 36: 9581-9581. DOI: 10.1200/Jco.2018.36.15_Suppl.9581 |
0.53 |
|
| 2018 |
Izar B, Jerby-Arnon L, Rotem A, Shah P, Liu D, Zhang G, Schilling B, Rozenblatt-Rosen O, Boland GM, Hodi FS, Flaherty K, Van Allen EM, Johnson BE, Schadendorf D, Yoon C, et al. Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. Journal of Clinical Oncology. 36: 3074-3074. DOI: 10.1200/Jco.2018.36.15_Suppl.3074 |
0.363 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran AA, Torrano J, Hammerlindl S, Zhang G, Somasundaram R, Sturm RA, Haass NK, Flaherty K, Herlyn M, Schaider H. Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma Cancer Research. 78: 5833-5833. DOI: 10.1158/1538-7445.Am2018-5833 |
0.598 |
|
| 2018 |
Emran A, Marzese DM, Menon DR, Stark M, Torrano J, Hammerlindl H, Zhang G, Brafford P, Hammerlindl S, Gupta D, Mills GB, Lu Y, Flaherty K, Sturm R, Hoon DSB, et al. Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma Australasian Journal of Dermatology. 59: 31-32. DOI: 10.1111/Ajd.16_12815 |
0.304 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran A, Torrano J, Hammerlindl S, Zhang G, Krause L, Somasundaram R, Sturm R, Haass NK, Flaherty K, Herlyn M, Schaider H. 1237 Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi-resistant melanoma Journal of Investigative Dermatology. 138. DOI: 10.1016/J.Jid.2018.03.1252 |
0.519 |
|
| 2017 |
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports. 21: 1953-1967. PMID 29141225 DOI: 10.1016/J.Celrep.2017.10.021 |
0.523 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.547 |
|
| 2017 |
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 28953887 DOI: 10.1038/Nature24040 |
0.58 |
|
| 2017 |
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 8: 607. PMID 28928360 DOI: 10.1038/S41467-017-00452-4 |
0.611 |
|
| 2017 |
Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, et al. A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discovery. PMID 28899863 DOI: 10.1158/2159-8290.Cd-17-0741 |
0.535 |
|
| 2017 |
Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 32: 377-391.e9. PMID 28898698 DOI: 10.1016/J.Ccell.2017.08.004 |
0.513 |
|
| 2017 |
Leu JI, Barnoud T, Zhang G, Tian T, Wei Z, Herlyn M, Murphy ME, George DL. Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function. Oncotarget. PMID 28484090 DOI: 10.18632/Oncotarget.17321 |
0.542 |
|
| 2017 |
Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, et al. Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Research. PMID 28473531 DOI: 10.1158/0008-5472.Can-16-1768 |
0.491 |
|
| 2017 |
Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, ... ... Zhang G, et al. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 8: 25395-25417. PMID 28445987 DOI: 10.18632/Oncotarget.15915 |
0.469 |
|
| 2016 |
Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. Plos Genetics. 12: e1006518. PMID 27977682 DOI: 10.1371/Journal.Pgen.1006518 |
0.582 |
|
| 2016 |
Wu LW, Zhang G, Herlyn M. Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. Molecular & Cellular Oncology. 3: e1179381. PMID 27652325 DOI: 10.1080/23723556.2016.1179381 |
0.55 |
|
| 2016 |
Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, ... Zhang G, et al. PIM kinases as therapeutic targets against advanced melanoma. Oncotarget. PMID 27448973 DOI: 10.18632/Oncotarget.10703 |
0.589 |
|
| 2016 |
Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, et al. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. PMID 27210749 DOI: 10.1016/J.Celrep.2016.04.073 |
0.56 |
|
| 2016 |
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of Clinical Investigation. PMID 27043285 DOI: 10.1172/Jci82661 |
0.582 |
|
| 2016 |
Wu LW, Zhang G, Herlyn M. Repurposing an HIV drug to improve efficacy of targeted therapy in melanoma Translational Cancer Research. 5. DOI: 10.21037/8186 |
0.6 |
|
| 2016 |
Rebecca VW, Nicastri M, McGlaughlin N, McAfee Q, Zhang G, Alicea GM, Piao S, Fennelly C, Murugan S, Wei Z, Mills GB, Lu Y, Herlyn M, Winkler JD, Amaravadi RK. Abstract 1018: Structural features of novel dimeric quinacrines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage Cancer Research. 76: 1018-1018. DOI: 10.1158/1538-7445.Am2016-1018 |
0.472 |
|
| 2015 |
Hew K, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford PA, Guo W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482043 DOI: 10.1158/1078-0432.Ccr-15-0534 |
0.372 |
|
| 2015 |
Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, et al. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell & Melanoma Research. 28: 431-41. PMID 25903073 DOI: 10.1111/Pcmr.12379 |
0.521 |
|
| 2015 |
Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25619837 DOI: 10.1038/Onc.2014.432 |
0.431 |
|
| 2015 |
Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, et al. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1652-64. PMID 25617424 DOI: 10.1158/1078-0432.Ccr-14-1554 |
0.554 |
|
| 2015 |
Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 11: 60-74. PMID 25484078 DOI: 10.4161/15548627.2014.984273 |
0.558 |
|
| 2015 |
Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/Pcmr.12330 |
0.555 |
|
| 2015 |
Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J. Abstract POSTER-THER-1431: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1431 |
0.471 |
|
| 2015 |
Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F. Abstract AS31: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As31 |
0.444 |
|
| 2015 |
Webster MR, Xu M, Kinzler K, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang V, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, et al. Abstract B27: Wnt5A-expressing melanoma cells show classical markers of senescence following radiation and therapeutic stress, but retain the ability to metastasize and proliferate at distant sites Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B27 |
0.481 |
|
| 2015 |
Somasundaram R, Zhang G, Wagner SN, Fukunaga-Kalabis M, Herlyn M. Abstract 420: The role of tumor microenvironment in therapy resistance and melanoma progression Cancer Research. 75: 420-420. DOI: 10.1158/1538-7445.Am2015-420 |
0.624 |
|
| 2015 |
Menon DR, Das S, Krepler C, Vultur A, Zhang G, Haass N, Soyer PH, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H. Abstract 2684: An early innate stress response precedes acquired drug resistance in melanoma Cancer Research. 75: 2684-2684. DOI: 10.1158/1538-7445.Am2015-2684 |
0.557 |
|
| 2015 |
Hew K, Miller P, El-Ashry D, Wei Z, Sun J, Zhang G, Guo W, Brafford P, Mills G, Slingerland J, Simpkins F. The effects of combined MEK inhibition and antiestrogen therapy in the treatment of ovarian cancer Gynecologic Oncology. 137: 182. DOI: 10.1016/J.Ygyno.2015.01.457 |
0.328 |
|
| 2014 |
Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25417704 DOI: 10.1038/Onc.2014.372 |
0.545 |
|
| 2014 |
Zhang G, Herlyn M. Linking SOX10 to a slow-growth resistance phenotype. Cell Research. 24: 906-7. PMID 24853952 DOI: 10.1038/Cr.2014.67 |
0.559 |
|
| 2014 |
Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 124: 1406-17. PMID 24569374 DOI: 10.1172/Jci70454 |
0.611 |
|
| 2014 |
Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, et al. 93 A stress induced early innate response causes multi-drug tolerance in melanoma European Journal of Cancer. 50: 34-34. DOI: 10.1016/S0959-8049(14)70219-9 |
0.463 |
|
| 2013 |
Rasanen K, Sriswasdi S, Valiga A, Tang HY, Zhang G, Perego M, Somasundaram R, Li L, Speicher K, Klein-Szanto AJ, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Molecular & Cellular Proteomics : McP. 12: 3778-92. PMID 24037664 DOI: 10.1074/Mcp.M113.029587 |
0.566 |
|
| 2013 |
Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Reports. 3: 1252-65. PMID 23562156 DOI: 10.1016/J.Celrep.2013.03.004 |
0.53 |
|
| 2013 |
Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Molecular Cancer Research : McR. 11: 219-29. PMID 23303345 DOI: 10.1158/1541-7786.Mcr-12-0547-T |
0.537 |
|
| 2013 |
Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G, Fukunaga-Kanabis M, Perez-Lorenzo R, Zheng B, Silvers DN, Brunner G, Wang S, Rabadan R, Cordon-Cardo C, Celebi JT. GAB2 induces tumor angiogenesis in NRAS-driven melanoma Oncogene. 32: 3627-3637. PMID 22926523 DOI: 10.1038/Onc.2012.367 |
0.45 |
|
| 2013 |
Balaburski G, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. Abstract 1683: Autophagy inhibition for cancer therapy. Cancer Research. 73: 1683-1683. DOI: 10.1158/1538-7445.Am2013-1683 |
0.482 |
|
| 2012 |
Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? The Journal of Investigative Dermatology. 132: 2133-4. PMID 22895446 DOI: 10.1038/Jid.2012.183 |
0.505 |
|
| 2012 |
Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell & Melanoma Research. 25: 493-505. PMID 22498258 DOI: 10.1111/J.1755-148X.2012.01005.X |
0.513 |
|
| 2012 |
Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G, Xu X. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 31: 1649-60. PMID 21860424 DOI: 10.1038/Onc.2011.366 |
0.466 |
|
| 2012 |
Ge Y, Azuma R, Gekonge B, Lopez-Coral A, Xiao M, Zhang G, Xu X, Montaner LJ, Wei Z, Herlyn M, Wang T, Kaufman RE. Induction of metallothionein expression during monocyte to melanoma-associated macrophage differentiation Frontiers in Biology. 7: 359-367. DOI: 10.1007/S11515-012-1237-8 |
0.515 |
|
| 2011 |
Räsänen KA, Basu D, Montone K, Zhang G, Rustgi A, Herlyn M. Abstract 523: Modeling the crosstalk between head and neck carcinomas and fibroblasts that underlies malignant invasion and drug resistance Cancer Research. 71: 523-523. DOI: 10.1158/1538-7445.Am2011-523 |
0.475 |
|
| 2011 |
Zhang G, Herlyn M. Abstract 1244: The requirement of autophagy pathway for drug-induced senescence in human melanoma cells by AZD1152 Cancer Research. 71: 1244-1244. DOI: 10.1158/1538-7445.Am2011-1244 |
0.604 |
|
| 2010 |
Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, Rustgi AK, Lee JT, Weinstein GS, Herlyn M. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene. 29: 4170-82. PMID 20498638 DOI: 10.1038/Onc.2010.170 |
0.572 |
|
| 2009 |
Basu D, Nguyen T, Montone K, Zhang G, Wang LP, Rustgi A, Lee J, Weinstein G, Herlyn M. Abstract C77: A mesenchymal‐like subpopulation within squamous cell carcinomas with chemotherapy resistance and phenotypic plasticity Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C77 |
0.581 |
|
| Show low-probability matches. |